RBC Capital Reiterates Sector Perform on Inovio Pharmaceuticals, Maintains $11 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Gregory Renza has reiterated a 'Sector Perform' rating on Inovio Pharmaceuticals (NASDAQ:INO) and maintained an $11 price target on the stock.
March 07, 2024 | 2:18 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
RBC Capital maintains a 'Sector Perform' rating and an $11 price target on Inovio Pharmaceuticals, indicating a neutral outlook.
The reiteration of the 'Sector Perform' rating and the maintenance of the $11 price target by RBC Capital suggests a neutral short-term impact on INO's stock price. The analyst's view indicates that the stock is currently valued appropriately, suggesting no significant price movement expected in the immediate future.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 90